Dr Reddys Laboratories Ltd (RDY) stock
RDYNYSEPharmaceutical PreparationsFiscal year ends March 31
Financials through fiscal 2026, year ended Mar 31, 2026Score 7/30
$14.89+0.06 (+0.40%)
Close on Nov 20, 2026Market cap $12.43BP/E 27.3Yield 0.57%
Dr Reddys Laboratories gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
For fiscal 2026 it was ₹177.26B, down 6.9% from the year before. Over ten years it grew 6.7% a year on average. The highest annual figure on record is ₹190.43B in fiscal 2025.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | ₹177.26B | -6.9% |
| FY2025 | Mar 31, 2025 | ₹190.43B | +16.4% |
| FY2024 | Mar 31, 2024 | ₹163.61B | +17.4% |
| FY2023 | Mar 31, 2023 | ₹139.34B | +22.4% |
| FY2022 | Mar 31, 2022 | ₹113.84B | +10.4% |
| FY2021 | Mar 31, 2021 | ₹103.08B | +9.6% |
| FY2020 | Mar 31, 2020 | ₹94.01B | +12.7% |
| FY2019 | Mar 31, 2019 | ₹83.43B | +9.3% |
| FY2018 | Mar 31, 2018 | ₹76.30B | -2.6% |
| FY2017 | Mar 31, 2017 | ₹78.36B | -15.1% |
| FY2016 | Mar 31, 2016 | ₹92.28B | – |
See a number that looks wrong?